Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Select your species
Human Glypican 3 Kit ELISA pour Sandwich ELISA - ABIN414787
Tangkijvanich, Chanmee, Komtong, Mahachai, Wisedopas, Pothacharoen, Kongtawelert: Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. dans Journal of gastroenterology and hepatology 2010
Show all 5 Pubmed References
Human Glypican 3 Kit ELISA pour Sandwich ELISA - ABIN365731
Yao, Yao, Bian, Wu, Yan, Yu, Qiu, Yang, Zhang, Sai, Chen: Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. dans Hepatobiliary & pancreatic diseases international : HBPD INT 2013
Show all 3 Pubmed References
MOSPD1 is a possible candidate gene for DORV (Montrer GDF1 Kits ELISA), probably in combination with GPC3. Further studies of the combined functions of MOSPD1 and GPC3 are needed, and identification of additional patients with MOSPD1 and GPC3 duplication should be pursued
Glypican-3 is correlated with the clinical malignant behavior of hepatocellular carcinoma and its phenotype changes from positive to negative during tumor cells differentia- tion.
The diagnostic sensitivity for hepatocellular carcinoma increased to 72.8% (206 of the 283) when glypican 3 was combined with alpha-fetoprotein (Montrer AFP Kits ELISA).
The lncRNA glypican 3 antisense transcript 1 (GPC3-AS1 (Montrer PTGDR Kits ELISA)) has been reported to be a potential biomarker for hepatocellular carcinoma (HCC (Montrer FAM126A Kits ELISA)) screening. We observed a significant upregulation of GPC3-AS1 (Montrer PTGDR Kits ELISA) in HCC (Montrer FAM126A Kits ELISA). Increased expression of GPC3-AS1 (Montrer PTGDR Kits ELISA) was associated with alpha-fetoprotein (Montrer AFP Kits ELISA), tumor size, microvascular invasion, encapsulation, Barcelona Clinic Liver Cancer stage, and worse prognosis of HCC (Montrer FAM126A Kits ELISA) patients.
study provides the first evidence that GPC3 can modulate the PCSK9 (Montrer PCSK9 Kits ELISA) extracellular activity as a competitive binding partner to the LDLR (Montrer LDLR Kits ELISA) in HepG2 cells.
By subsequent Sanger sequencing of genomic DNA we could map the chromosomal break points to define a deletion size of 43,617 bp including exons 5 and 6 of the GPC3 gene.
This is the first study in which the optimal HLA-A*0201 GPC3 epitopes were screened from a large number of candidates predicted by three software. The optimized HLA-A*0201 GPC3 peptides will provide new epitope candidates for hepatocellular carcinoma (HCC (Montrer FAM126A Kits ELISA)) immunotherapy.
GPC3 and KRT19 (Montrer KRT19 Kits ELISA) overexpression are associated with carcinogenesis, progression, and poor prognosis in patients with PDAC and a valuable biomarker for diagnosis of PDAC.
The clinical implication of GPC3 detection and targeting in the management of patients with hepatocellular carcinoma. Review.
Glypican 3 expression showed a significant difference between endometrioid endometrial carcinoma and serous endometrial carcinoma, and it was significantly correlated with tumor grade, stage and myometrial invasion
Data show that notum (Montrer NOTUM Kits ELISA) and glypican-1 (Montrer GPC1 Kits ELISA) and glypican-3 gene expression during colorectal cancer (CRC (Montrer SCRIB Kits ELISA)) development and present evidence to suggest them as potential new biomarkers of CRC (Montrer SCRIB Kits ELISA) pathogenesis.
Coupling of pGPC3 to liposomes was essential for effective priming of GPC3-specific CTLs.
The expression of GPC-3 was altered by DEN treatment.
Data suggest that GPC3 down-regulates hepatocyte proliferation by binding to hedgehog (Montrer SHH Kits ELISA) (HH) and down-regulating the HH signaling pathway and binding with CD81 (Montrer CD81 Kits ELISA), thus making it unavailable to bind to Hhex (Montrer HHEX Kits ELISA) and causing its nuclear translocation.
Finding represents a rare four layer genomic overlap consisting of growth associated quantitative trait locus (QTL), body mass associated Gpc3 gene, highly conserved miRNA gene and mature miRNA seed SNP identified in the lean mouse.
Hepatocyte overexpression of GPC3 suppresses hepatocyte proliferation and liver regeneration and alters gene expression profiles.
glypican-3 is involved in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma
GPC3 inhibits the PI3K/Akt (Montrer AKT1 Kits ELISA) anti-apoptotic pathway while it stimulates the p38MAPK (Montrer MAPK14 Kits ELISA) stress-activated one in murine mammary adenocarcinoma LM3 cells
Gpc3 function in development of Simpson-Golabi-Behmel syndrome is IGF-independent
GPC3 knockout mice exhibit alterations in the Wnt (Montrer WNT2 Kits ELISA) signaling pathway, which is also associated with the regulation of cell proliferation
Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants.
, glypican proteoglycan 3
, heparan sulphate proteoglycan
, intestinal protein OCI-5
, secreted glypican-3
, defective in Simpson-Golabi-Behmel overgrowth syndrome
, proteoglycan GPC3
, Intestinal protein OCI-5